title: Autologous bone marrow transplantation for acute leukemia: results and prognostic factors in 90 consecutive patients.
abstract: The results of autologous bone marrow transplantation (ABMT) in acute leukemia (AL) and the prognostic factors for outcome were analyzed in a series of 90 consecutive patients treated at a single institution (mean +/- SD age: 25 +/- 11 years). Diagnosis was: AML (n = 43), ALL (n = 44), acute undifferentiated leukemia (n = 2) and acute bilineage (n = 1). Disease stage at ABMT was: first complete remission (CR1) 46 cases, CR2 33, other stages 11. Conditioning consisted of cyclophosphamide and total body irradiation in 88 patients. The 3 year probability of disease-free survival (DFS) was influenced by disease stage at ABMT: CR1 48%, CR2 28%, CR3 plus CR4 15%. The characteristics associated with a high probability of relapse were: in AML a FAB subtype other than M1 or M3 (p = 0.01) and in ALL an interval between CR1 and ABMT of < 3 months (p = 0.002). A WBC > 15 x 10(9)/l at diagnosis (p = 0.01), splenomegaly at diagnosis (p = 0.002) and time to CR1 > 4 weeks (p = 0.06) increased the risk of relapse in the entire group in CR1. In multivariate analysis, WBC at diagnosis (p = 0.006) and disease stage at ABMT (p = 0.03) independently influenced DFS. This study confirms the encouraging results of ABMT in CR1 but further antileukemia measures are necessary in patients with adverse prognostic features.
authors.affiliation: Postgraduate School of Hematology, Hospital Clínic, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Sierra
authors.forename: A
authors.initials: A
authors.lastname: Grañena
authors.forename: J
authors.initials: J
authors.lastname: García
authors.forename: A
authors.initials: A
authors.lastname: Valls
authors.forename: E
authors.initials: E
authors.lastname: Carreras
authors.forename: M
authors.initials: M
authors.lastname: Rovira
authors.forename: C
authors.initials: C
authors.lastname: Canals
authors.forename: E
authors.initials: E
authors.lastname: Martínez
authors.forename: C
authors.initials: C
authors.lastname: Puntí
authors.forename: M
authors.initials: M
authors.lastname: Algara
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000592:standards*; D002648:Child; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007938:Leukemia / Q000453:epidemiology / Q000401:mortality / Q000628:therapy*; D007951:Leukemia, Myeloid / Q000453:epidemiology / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000453:epidemiology / Q000401:mortality / Q000628:therapy; D011379:Prognosis; D012008:Recurrence; D015996:Survival Rate; D014182:Transplantation, Autologous; D014916:Whole-Body Irradiation
chemical_list: D003520:Cyclophosphamide